Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Alnylam Pharmaceuticals, Inc. (ALNY) -- Ignore unavailable to you. Want to Upgrade?

To: tuck who wrote (125)	9/26/2007 8:44:40 PM
From: hmpa	Read Replies (1) \| Respond to of 166

Zacks analyst never liked ALNY, and for some reason was always somewhat behind on this stock: had target $9.50 in 08/2006, 10.50 in 09/2006 - so the fact they now have a target above the share price may be construed as positive (or negative, if one is a contrarian...). If one subscribes to the idea that any projects earlier than Ph II don't have any value, and science has a negative value (makes you spend money w/o payback) it forces to valuate based on peer company pricing which he now did. With the chart the way it looks I wouldn't be selling naked calls (I did buy some Dec puts for the binary though...)